Viloxazine 100 mg 24HR Extended Release Oral Capsule
RxNorm 2536548
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2536548 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: viloxazine 100 mg 24HR Extended Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
24 HR viloxazine 100 mg Extended Release Oral Capsule
(Atom ID: 12623721)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely viloxazine (as viloxazine hydrochloride) 100 mg/1 each prolonged-release oral capsule (clinical drug)
(Atom ID: 12727580)
PTPrescribable
Designated preferred name (PT):
Viloxazine (as viloxazine hydrochloride) 100 mg prolonged-release oral capsule
(Atom ID: 12728036)
SYPrescribable
Synonym (SY):
Viloxazine 100 mg (as viloxazine HCl 115 mg) 24 HR Extended Release Oral Capsule
(Atom ID: 12623737)
PSNPrescribable
Prescribable Name (PSN):
Viloxazine 100 mg 24HR Extended Release Oral Capsule
(Atom ID: 12623735)
Patient Education
Viloxazine
Viloxazine is used as part of a total treatment program to increase the ability to pay attention and decrease impulsiveness and hyperactivity in children 6 to 17 years of age with attention deficit hyperactivity disorder (ADHD). Viloxazine is in a class of medications called selective norepinephrine reuptake inhibitors. It works by increasing the levels of norepinephrine, a natural substance in the brain that is needed to control behavior.
[Learn More]
* Please review the disclaimer below.